Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728001 | 0.83 | HCRTR1 (0.42) | HCRTR1HCRTR2ALDH1A1RXFP1 | |
| SCHEMBL2134232 | 0.82 | HCRTR1 (0.49) | HCRTR1HCRTR2KCNH2LTC4S | |
| SCHEMBL2132039 | 0.80 | HCRTR1 (0.55) | HCRTR1HCRTR2KCNH2LTC4S | |
| SCHEMBL2130316 | 0.80 | HCRTR1 (0.82) | HCRTR1HCRTR2KCNH2LTC4S | |
| SCHEMBL2135421 | 0.79 | HCRTR1 (0.65) | HCRTR1HCRTR2KCNH2LTC4S | |
| SCHEMBL2134161 | 0.79 | HCRTR1 (0.49) | HCRTR1HCRTR2KCNH2LTC4S | |
| SCHEMBL2131256 | 0.79 | HCRTR2 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL2135914 | 0.78 | HCRTR1 (0.49) | HCRTR1HCRTR2KCNH2LTC4SALDH1A1 | |
| SCHEMBL2130550 | 0.78 | HCRTR1 (0.52) | HCRTR1HCRTR2KCNH2LTC4SALDH1A1 | |
| SCHEMBL6422576 | 0.77 | HCRTR1 (0.41) | HCRTR1HCRTR2KCNH2LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | claimed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | claimed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR1 2/4885HCRTR2 1/4885KCNH2 1356/4885 |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | REN, PKD1, NR3C2 | HCRTR1 3936/4885HCRTR2 3715/4885KCNH2 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.